|
TW528755B
(en)
|
1996-12-24 |
2003-04-21 |
Glaxo Group Ltd |
2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
|
|
YU44900A
(en)
|
1998-01-31 |
2003-01-31 |
Glaxo Group Limited |
2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
|
|
KR100568658B1
(en)
*
|
1998-02-26 |
2006-04-07 |
아벤티스 파마슈티칼스 인크 |
6,9-disubstituted 2- [trans- (4-aminocyclohexyl) amino] purine
|
|
US6479487B1
(en)
|
1998-02-26 |
2002-11-12 |
Aventis Pharmaceuticals Inc. |
6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
|
|
US6413974B1
(en)
|
1998-02-26 |
2002-07-02 |
Aventis Pharmaceuticals Inc. |
6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
|
|
US6495528B1
(en)
|
1998-06-23 |
2002-12-17 |
Smithkline Beecham Corporation |
2-(Purin -9-yl)-tetrahydrofuran-3,4-diol derivatives
|
|
JP2002193967A
(en)
*
|
2000-07-10 |
2002-07-10 |
Sumika Fine Chemicals Co Ltd |
Production method of 2,6-dichloropurine
|
|
US6861524B2
(en)
|
2000-10-31 |
2005-03-01 |
Aventis Pharmaceuticals Inc. |
Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
|
|
AR044519A1
(en)
|
2003-05-02 |
2005-09-14 |
Novartis Ag |
DERIVATIVES OF PIRIDIN-TIAZOL AMINA AND PIRIMIDIN-TIAZOL AMINA
|
|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
|
PE20060272A1
(en)
|
2004-05-24 |
2006-05-22 |
Glaxo Group Ltd |
(2R, 3R, 4S, 5R, 2'R, 3'R, 4'S, 5'S) -2.2 '- {TRANS-1,4-CYCLOHEXANODIYLBIS- [IMINO (2 - {[2- (1-METHYL- 1H-IMIDAZOL-4-IL) ETHYL] AMINO} -9H-PURIN-6,9-DIYL)]} BIS [5- (2-ETHYL-2H-TETRAZOLE-5-IL) TETRAHYDRO-3,4-FURANODIOL] AS AN A2A AGONIST
|
|
GB0424284D0
(en)
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
GB0514809D0
(en)
|
2005-07-19 |
2005-08-24 |
Glaxo Group Ltd |
Compounds
|
|
EP2532677A1
(en)
|
2005-10-21 |
2012-12-12 |
Novartis AG |
Human antibodies against il13 and therapeutic uses
|
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
|
JP2010504933A
(en)
|
2006-09-29 |
2010-02-18 |
ノバルティス アーゲー |
Pyrazolopyrimidines as PI3K lipid kinase inhibitors
|
|
BRPI0718266A2
(en)
|
2006-10-30 |
2014-01-07 |
Novartis Ag |
HETEROCYCLIC COMPOUNDS AS ANTI-INFLAMMATORY AGENTS.
|
|
JP5584138B2
(en)
|
2008-01-11 |
2014-09-03 |
ノバルティス アーゲー |
Pyrimidines as kinase inhibitors
|
|
ES2396023T3
(en)
|
2009-01-29 |
2013-02-18 |
Novartis Ag |
Substituted benzimidazoles for the treatment of astrocytomas
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
BR112012003262A8
(en)
|
2009-08-12 |
2016-05-17 |
Novartis Ag |
Heterocyclic Hydrazone Compounds and Their Uses to Treat Cancer and Inflammation
|
|
UA111579C2
(en)
|
2009-08-17 |
2016-05-25 |
Інтеллікіне Ллк |
Heterocyclic 2-Aminobenzo [d] Oxazole Derivatives, Pharmaceutical Composition Based on Them and Their Applications for Disease Treatment
|
|
IN2012DN01453A
(en)
|
2009-08-20 |
2015-06-05 |
Novartis Ag |
|
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
|
UY33597A
(en)
|
2010-09-09 |
2012-04-30 |
Irm Llc |
COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE TRK
|
|
WO2012107500A1
(en)
|
2011-02-10 |
2012-08-16 |
Novartis Ag |
[1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
|
BR112013021638A2
(en)
|
2011-02-25 |
2016-08-02 |
Irm Llc |
"trk inhibiting compounds, their use and compositions comprising them"
|
|
UY34329A
(en)
|
2011-09-15 |
2013-04-30 |
Novartis Ag |
TRIAZOLOPIRIDINE COMPOUNDS
|
|
US9174994B2
(en)
|
2011-11-23 |
2015-11-03 |
Intellikine, Llc |
Enhanced treatment regimens using mTor inhibitors
|
|
MX371119B
(en)
|
2012-04-03 |
2020-01-17 |
Novartis Ag |
Combination products with tyrosine kinase inhibitors and their use.
|
|
HK1219421A1
(en)
|
2013-03-15 |
2017-04-07 |
因特利凯有限责任公司 |
Combination of kinase inhibitors and uses thereof
|
|
TW201605450A
(en)
|
2013-12-03 |
2016-02-16 |
諾華公司 |
Combination of Mdm2 inhibitor and BRAF inhibitor and their use
|
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
|
US10195208B2
(en)
|
2014-07-31 |
2019-02-05 |
Novartis Ag |
Combination therapy
|
|
CN111683976B
(en)
|
2018-02-05 |
2022-11-18 |
生物辐射实验室股份有限公司 |
Chromatography resins with anion-exchange-hydrophobic mixed-mode ligands
|
|
TW202140550A
(en)
|
2020-01-29 |
2021-11-01 |
瑞士商諾華公司 |
Methods of treating an inflammatory or obstructive airway disease using anti-tslp antibody
|